COMBINATION THERAPY OF EMPAGLIFLOZIN AND LINAGLIPTIN AS SECOND-LINE THERAPY IN TYPE 2 DIABETES

Amit Modgil, Amit Kumar Singh, Amitav Mohanty, Antony Benedict, Arijit Samanta

Abstract


Many pharmacotherapies are now available for glycaemic control in type 2 diabetes (T2D); however, the management of T2D remains complex and challenging, in part due to the limiting side effects of current therapies as well as the variable pathogenesis and progressive natural history of T2D. Thus, the quest to develop therapeutic agents with novel mechanisms of action that might fulfill the unmet needs of the currently available therapies continues1.


Keywords


urinary glucose excretion (UGE), systolic blood pressure (SBP), type 2 diabetes (T2D)

Full Text:

PDF

Refbacks

  • There are currently no refbacks.